Atara Biotherapeutics, Inc.
General ticker "ATRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $119.9M (TTM average)
Atara Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 0.5%.
Estimated limits based on current volatility of 6.7%: low 9.84$, high 10.69$
Factors to consider:
- Total employees count: 153 (-32.0%) as of 2024
- Top business risk factors: Regulatory and compliance, Clinical trial disruptions, Market competition, Supply chain disruptions, Economic downturns and volatility
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.41$, 26.48$]
- 2026-12-31 to 2027-12-31 estimated range: [4.80$, 16.45$]
Financial Metrics affecting the ATRA estimates:
- Positive: with PPE of 5.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: Operating profit margin, % of 29.69 > 18.39
- Positive: Return on assets ratio (scaled to [-100,100]) of 61.77 > 6.06
- Positive: Investing cash flow per share per price, % of 8.23 > -0.60
- Negative: Shareholder equity ratio, % of -190.27 <= 19.24
Short-term ATRA quotes
Long-term ATRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $8.57MM | $128.94MM | $120.77MM |
| Operating Expenses | $284.58MM | $212.38MM | $84.91MM |
| Operating Income | $-276.01MM | $-83.44MM | $35.86MM |
| Non-Operating Income | $-0.10MM | $-1.98MM | $-3.14MM |
| Interest Expense | $5.29MM | $4.62MM | $3.79MM |
| R&D Expense | $224.78MM | $151.48MM | $37.45MM |
| Income(Loss) | $-276.11MM | $-85.42MM | $32.72MM |
| Taxes | $0.01MM | $-0.01MM | $0.03MM |
| Net Income(Loss)* | $-276.13MM | $-85.40MM | $32.69MM |
| Stockholders Equity | $-99.23MM | $-97.28MM | $-38.50MM |
| Inventory | $9.71MM | $10.65MM | $0.00MM |
| Assets | $165.50MM | $109.10MM | $20.23MM |
| Operating Cash Flow | $-192.98MM | $-68.72MM | $-50.94MM |
| Capital expenditure | $1.22MM | $0.25MM | $0.00MM |
| Investing Cash Flow | $123.87MM | $8.62MM | $18.15MM |
| Financing Cash Flow | $2.01MM | $59.28MM | $16.10MM |
| Earnings Per Share** | $-65.18 | $-11.41 | $2.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.